Regular ArticleSafety and Effectiveness of Long-Term Interferon Gamma Therapy in Patients with Chronic Granulomatous Disease☆
References (0)
Cited by (53)
Human CD40 ligand deficiency dysregulates the macrophage transcriptome causing functional defects that are improved by exogenous IFN-γ
2017, Journal of Allergy and Clinical ImmunologyChronic granulomatous disease as an SOS call for multicenter cooperative effort to prevent infections: A meta-analysis of the treatments
2016, Annals of Allergy, Asthma and ImmunologyCitation Excerpt :The main drawback of interferon therapy is its adverse effect profile, which can lead to decreased adherence and dose reductions, both of which limit the effectiveness of treatment20; fever and headache are the most frequent adverse effects.20 However, some open-label studies evaluated the interferon gamma prophylaxis in patients with CGD, concluding that it is safe, without serious long-term adverse effects.26,27 This meta-analysis has the following limitations.
Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity
2016, Molecular Therapy - OncolyticsCitation Excerpt :In the clinic, it has been shown that that local injection of IFNσ in skin lesions of breast cancer patients resulted in partial regression.11 Also, recombinant human IFNσ-1b has successfully been used to delay progression of microbial infections in chronic granulomatous disease,12 but its use in human cancer treatment has given mixed results.13–16 One of the reasons for the limited efficacy was attributed to the very short half-life of IFNσ in serum and therefore, local expression is a more promising approach.17
Pulmonary Complications of Primary Immunodeficiencies
2015, Murray and Nadel's Textbook of Respiratory Medicine: Volume 1,2, Sixth EditionClinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: An Italian multicenter study
2008, Clinical ImmunologyCitation Excerpt :Long-term oral prophylaxis with cotrimoxazole and itraconazole has been shown to reduce the rate of infection among patients with CGD [8–11]. A further reduction of the infection rate has been described with IFNγ [12–15]. There is a wide range of clinical variability in patients with CGD.
Cytokines and anti-cytokines as therapeutics - An update
2008, European Journal of Pharmacology
- ☆
communicated by Ernest , Beutler, M.D.12/21/95